Experimental coronavirus treatment leronlimab shows ‘very promising’ response in some COVID-19 patients
April 13, 2020 / By James Rogers | Fox News
The experimental coronavirus treatment leronlimab has shown a “very promising” response in COVID-19 patients with mild-to-moderate symptoms, according to developer CytoDyn.
Leronlimab is a viral-entry inhibitor that targets HIV and breast cancer. The drug has also been attracting attention as a potential coronavirus treatment. In a statement released Monday CytoDyn gave an update on over 30 patients COVID-19 patients recently treated with leronlimab in more than 4 hospitals and clinics across the U.S. Patients have received leronlimab as part of Emergency Investigational New Drug (EINDs) treatments authorized by the FDA and two CytoDyn clinical trials.
“More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA),” the biotech explained. “Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen.”
Leronlimab is one of a number of drugs in the spotlight as the world scrambles to contain the coronavirus pandemic. Experts, however, have warned that people should not take drugs unless prescribed by a doctor.
